183 related articles for article (PubMed ID: 18654117)
1. Angiogenesis inhibition in non-clear cell renal cancer.
Stadler W
Clin Adv Hematol Oncol; 2008 Jul; 6(7):507-9. PubMed ID: 18654117
[No Abstract] [Full Text] [Related]
2. [Development of angiogenesis inhibitory combination therapies for treatment of renal cell carcinoma].
Bartsch G; Eggert K; Soker S; Fiedler W; Laack E; Volkmer BG; Gschwend J; Bokemeyer C; Hautmann R; Schuch G
Urologe A; 2007 Sep; 46(9):1289-90. PubMed ID: 17624513
[No Abstract] [Full Text] [Related]
3. Interview with professor Per-Anders Abrahamson: angiogenesis and renal cell carcinoma.
Abrahamson PA
Eur Urol; 2006 Sep; 50(3):609-11. PubMed ID: 16824676
[No Abstract] [Full Text] [Related]
4. [Renal cell carcinoma: the end of a tunnel?].
Ravaud A; Dilhuydy MS
Pathol Biol (Paris); 2006 May; 54(4):206-8. PubMed ID: 16530346
[No Abstract] [Full Text] [Related]
5. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.
Kuusk T; Albiges L; Escudier B; Grivas N; Haanen J; Powles T; Bex A
Angiogenesis; 2017 May; 20(2):205-215. PubMed ID: 28401381
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.
Sonpavde G; Willey CD; Sudarshan S
Expert Opin Investig Drugs; 2014 Mar; 23(3):305-15. PubMed ID: 24387233
[TBL] [Abstract][Full Text] [Related]
7. New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far?
Escudier B; Staehler M
Eur Urol; 2018 Jan; 73(1):1-3. PubMed ID: 28890247
[TBL] [Abstract][Full Text] [Related]
8. Angiopoietins and non-vascular endothelial growth factor antiangiogenic targets in advanced renal cell carcinoma.
Richey SL; Hutson TE
Cancer J; 2013; 19(4):307-10. PubMed ID: 23867511
[TBL] [Abstract][Full Text] [Related]
9. Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".
Alonso-Gordoa T; García-Bermejo ML; Grande E; Garrido P; Carrato A; Molina-Cerrillo J
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999623
[TBL] [Abstract][Full Text] [Related]
10. Axitinib (Inlyta) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2012 Jun; 54(1392):47-8. PubMed ID: 22683928
[No Abstract] [Full Text] [Related]
11. New therapies after failure of angiogenesis inhibitors.
Escudier B
Clin Adv Hematol Oncol; 2009 Aug; 7(8):512-4. PubMed ID: 19927977
[No Abstract] [Full Text] [Related]
12. [New therapeutics strategies in renal cell carcinoma].
Meric JB; Billemont B; Rixe O
Bull Cancer; 2010; 97():53-63. PubMed ID: 20418204
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab as first-line therapy for patients with brain metastases from renal carcinoma: a case series.
Zustovich F; Ferro A; Farina P
Clin Genitourin Cancer; 2014 Jun; 12(3):e107-10. PubMed ID: 24583162
[No Abstract] [Full Text] [Related]
14. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
de Bazelaire C; Alsop DC; George D; Pedrosa I; Wang Y; Michaelson MD; Rofsky NM
Clin Cancer Res; 2008 Sep; 14(17):5548-54. PubMed ID: 18765547
[TBL] [Abstract][Full Text] [Related]
15. [New treatment of metastatic renal cancer. The Danish Society of Clinical Oncology].
Sengeløv L; Geertsen PF;
Ugeskr Laeger; 2007 Mar; 169(12):1117. PubMed ID: 17394828
[No Abstract] [Full Text] [Related]
16. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival.
Zubac DP; Bostad L; Kihl B; Seidal T; Wentzel-Larsen T; Haukaas SA
J Urol; 2009 Nov; 182(5):2144-9. PubMed ID: 19758660
[TBL] [Abstract][Full Text] [Related]
17. Distinct angiogenic and non-angiogenic growth patterns of lung metastases from renal cell carcinoma.
Sardari Nia P; Hendriks J; Friedel G; Van Schil P; Van Marck E
Histopathology; 2007 Sep; 51(3):354-61. PubMed ID: 17727477
[TBL] [Abstract][Full Text] [Related]
18. [The advantages of antiangiogenics in neoadjuvant and adjuvant locally advanced and metastatic kidney cancer: two case studies].
Ferrière JM; Wallerand H; Bernhard JC; Cornu JN; Rouprêt M; Ravaud A
Prog Urol; 2008 Jul; 18 Suppl 4():S88-91. PubMed ID: 18706377
[TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenic therapy in renal cell carcinoma: Alone, in combination, or sequentially.
Figlin RA
Clin Adv Hematol Oncol; 2009 Oct; 7(10):662-5. PubMed ID: 20040906
[No Abstract] [Full Text] [Related]
20. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts.
Yalcin M; Bharali DJ; Lansing L; Dyskin E; Mousa SS; Hercbergs A; Davis FB; Davis PJ; Mousa SA
Anticancer Res; 2009 Oct; 29(10):3825-31. PubMed ID: 19846915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
